OSTX
OS Therapies Incorporated
Healthcare — Biotechnology
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
None
4 analysts
$1.60
(0.00%)
Target:
$9.40
(487.3%)
Price History
52-Week Range
Sign in to add OSTX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $80.61M |
| P/E Ratio (TTM) | - |
| Forward P/E | -8.42 |
| EPS (TTM) | $-1.07 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $9.40 |
| Analysts | 4 |
| Next Earnings | Aug 17, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 54.4 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.57 |
| 52-Week Low | $1.15 |
| 50-Day Avg | $1.77 |
| 200-Day Avg | $1.67 |
| Avg Volume | 785.1K |
| Volume | 564.8K |
Performance Analysis
NEUTRALOSTX presents a mixed picture with both positive and negative indicators.
~
Trading at 32% of its 52-week range.
~
RSI at 54.4 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 4 analysts.
+
Average analyst target of $9.40 implies 487.3% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:25 UTC
Back to Screener Export Report